Is that the peak sales only for the 4 indications though? Thats how I read it.
Jon mentioned a possible 100 other indications once and even if you used the same ultra conservative approach Hashan took and applied a 90% discount, that’s still 10 more possible conditions that 2591 could treat. Which would significant increase peak sales.
As he said - 2591 is a pipeline in a drug
NEU Price at posting:
$20.53 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)